Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical company focused on innovative drug delivery technologies, primarily through its Enhaze platform. This technology, based on the rHuPH20 ...

The IXP Lifesciences Catalyst Fund has a greenshoe option of Rs 100 crore with an investment horizon of 3-5 years targeting ...

With many biotechs and pharmas needing to fill impending revenue holes coming later in the decade, M&A is posed to pick up, but not until government and regulatory uncertainty settles down. Dealmaking ...

Biotech firm Phytome Life Sciences plans to establish a headquarters in Saudi Arabia in a bid to accelerate commercialization ...

With Chinese firms becoming major players in drug development, the traditional balance of power in global pharmaceuticals is ...

For example, Brittany found that drugs being developed by Generate were modified versions of existing antibodies, and that ...

(Corrects third to last paragraph to say "the erosion from LOEs (loss of exclusivity)", not "from LOEs (levels of evidence)") ...

The fund aims to build a portfolio of 20-25 companies that address gaps in services and products across pharmaceuticals, ...

Good news for the sector came January 23 when global pharmaceutical giant AstraZeneca plc announced an eye-popping $820 ...

Leading American genomic sequencing firm Illumina says it is evaluating Beijing’s announcement with hope of ‘positive ...

Of the 102 company launches or series A financings since October 2023, just nine had a woman at the helm, according to a ...